ARTICLE | Cover Story
Breaking MYC metabolism
June 19, 2014 7:00 AM UTC
The metabolic enzyme phosphoribosyl pyrophosphate synthetase 2 could represent a tractable way to modulate the notoriously undruggable oncogene MYC.1 The findings from a University of California, San Francisco team are licensed to Effector Therapeutics Inc. and provide a clue as to how the company plans to attack protein translation-related mechanisms in cancers.
The UCSF group now plans to identify specific inhibitors of phosphoribosyl pyrophosphate synthetase 2 (PRPS2) and wants to see if the mechanism is present in cancers promoted by oncogenes other than MYC (c-Myc)...